Payment overview · 2025
General Payments
$2,195.83
79 reported records · 21 companies
Healthcare provider profile · identity verified
Gary Weinstein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · DALLAS, TX · NPI 1275617920
Verified facts
What the public records show
CMS Open Payments records show Gary Weinstein, M.D. received $2,195.83 in general payments during 2025 across 79 reported records.
GlaxoSmithKline, LLC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ryaltris, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 655 claims for Trelegy Ellipta by this doctor in 2024.
Hikma Pharmaceuticals USA reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ryaltris as an associated drug or biological on 1245 records involving 1030 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ryaltris by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $471.20 | 21.5% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $446.18 | 20.3% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $227.75 | 10.4% | 8 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $214.69 | 9.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $176.16 | 8.0% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $84.74 | 3.9% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $82.06 | 3.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.88 | 3.2% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $68.64 | 3.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.65 | 2.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.99 | 2.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $39.02 | 1.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.04 | 1.6% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $33.24 | 1.5% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $32.21 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.77 | 1.4% | 2 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $21.20 | 1.0% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $20.82 | 0.9% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $19.84 | 0.9% | 1 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $17.47 | 0.8% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $16.28 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,195.83 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $389.75 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $285.09 | 14 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $214.69 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $176.16 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $165.25 | 7 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.68 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $84.74 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $82.06 | 4 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.07 | 6 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $68.64 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $61.13 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $58.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.49 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $32.21 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | HOSPIRA, INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ryaltris ryaltris |
2025 | Ryaltris | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 655 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
655 | 122 |
| Hikma Pharmaceuticals USA Exact reporting entity; no affiliate inference |
2025 | Ryaltris open payments reported associated product |
CMS Open Payments — General Payments 1245 supporting records · 1030 recipient NPIs · example record 1248215996 |
Ryaltris · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 655 | 122 |
| Montelukast Sodium | Montelukast Sodium | 446 | 131 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 64 |
| Azithromycin | Azithromycin | 144 | 70 |
| Prednisone | Prednisone | 132 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 44 |
| Methylprednisolone | Methylprednisolone | 108 | 80 |
| Breo Ellipta | Fluticasone/Vilanterol | 106 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 39 |
| Roflumilast | Roflumilast | 94 | 21 |
| Azelastine Hcl | Azelastine Hcl | 87 | 36 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 63 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 46 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 11 |
| Pirfenidone | Pirfenidone | 33 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ryaltris | Olopatadine Hcl/Mometasone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,195.83 · 79 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, Arikayce, Brinsupri, COMIRNATY, CUTAQUIG, DUPIXENT, FASENRA, GLASSIA, Hillrom - Vest System Model 105 Home Care, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, KISUNLA, MI CANCER SEEK, Monarch Platform, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, Ohtuvayre, PANZYGA, PAXLOVID, PREVNAR 20, Prolastin-C Liquid, Rapiblyk, Ryaltris, SHINGRIX, SMARTVEST, TAVNEOS, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, YUPELRI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ryaltris play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error